. 2018 Jul 30;9(8):213–226. doi: 10.1177/2040620718785363

Table 3.

Comparison of clinicopathological parameters in inhibitor-positive versus negative PWHA.

S. no.	Clinicopathological parameters	Total PWHA (n = 300)			Severe PWHA (n = 219)
S. no.	Clinicopathological parameters	Inhibitor positive (n = 29)	Inhibitor negative (n = 271)	p-value	Inhibitor positive (n = 29)	Inhibitor negative (n = 190)	p-value
1.	Mean age of patients at the time of study (years)	18.72 ± 10.17	17.85 ± 10.37	0.66	18.72 ± 10.17	17.38 ± 10.62	0.506
2.	Mean factor VIII level (%)	0.64 ± 0.19	1.35 ± 2.18	0.03^*	0.64 ± 0.19	0.68 ± 0.17	0.277
3.	Mean age at bleeding onset (years)	1.00 ± 0.82	3.46 ± 3.05	0.203	1.00 ± 0.82	2.71 ± 3.78	0.328
4.	Presence of family history	17 (55.6%)	178 (70.3%)	0.453	17 (55.6%)	124 (65.3%)	0.48
5.	Type of treatment
	Factor VIII only	13 (44.8%)	108 (39.9 %)	0.109	13 (44.8%)	77 (40.5%)	0.186
	Both factor VIII and blood/blood products	16 (55.2%)	136 (50.2%)		16 (55.2%)	93 (48.9%)
	Blood/blood products only	0 (0%)	27 (10%)		0 (0%)	20 (10.5%)
6.	Average factor VIII treatment courses/year
	1–5/year	0 (0%)	146 (55.0%)	0.002^*	0 (0%)	94 (49.5%)	<0.001^*
	6–10/year	17 (55.6%)	79 (27.5%)		17 (55.6%)	54 (28.4%)
	>10/year	12 (44.4%)	46 (17.5 %)		12 (44.4%)	42 (22.1%)
7.	Factor VIII replacement therapy
(a)	Mean age at 1st replacement therapy (years)	2.08 ± 0.83	6.17 ± 3.45	0.0055^*	2.08 ± 0.83	4.24 ± 5.27	0.017^*
(b)	Age at 1st replacement therapy
	⩽5 years	26 (89.66%)	178 (65.68%)	0.001^*	26 (89.66%)	107 (56.3%)	0.019^*
	>5 years	3 (10.34%)	93(34.0%)		3 (10.34%)	83 (43.7%)
8.	Annual factor intake (IU/kg/year)	4353.45 ± 3713.82	1636.35 ± 1352.29	0.0001^*	4353.45± 3713.82	2179.6 ± 1835.5	0.025^*

Applied unpaired Student’s t test for significance of scale/continuous data and Chi-square test for categorical data. *Significant (p-value <0.05).

PWHA, patients with hemophilia A.